ArticleFrontiers in bioengineering and biotechnology2026
Tissue-engineered dermal substitutes constructed by human embryonic stem cell-derived fibroblasts facilitate the repair of skin wounds.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tissue engineering is an efficient method for constructing functional skin equivalents to treat large-area skin wounds. However, the source of seed cells is limited. Objectives: Human embryonic stem cell (hESC) derivatives play an important role in tissue engineering. However, whether hESC-derived fibroblasts can be used as seed cells of tissue-engineered dermal substitutes has not been reported. Methods: In this study, we bypassed traditional induction methods, but rather directly induced Results: The hESCs line Conclusion: hESCs could be directly induced to differentiate into fibroblasts, which could be applied to the construction of tissue-engineered dermal substitutes and skin defect repair. Moreover, this EB-free induction strategy could offer significant advantages for clinical translation, including higher efficiency and better purity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.